Orathecin

Orathecin is an oral chemotherapy agent that has been investigated as a treatment for pancreatic cancer patients who are refractory/resistant to the limited available therapies in this disease.

The success of Orathecin could differ materially from those projected in the forward-looking statements as a result of known and unknown risk factors and uncertainties associated with drug development.